Peter Lio, MD - More Than Scratching the Surface: Optimizing Novel JAK Inhibitors for Improved Outcomes in Moderate-to-Severe Atopic Dermatitis

episode

CME in Minutes: Education in Dermatology not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

MIDWEEK RUB | Should Lachie Neale Get Off? Full Grand Final Preview + Brownlow Wrap 38 min · 23 Sep 2026 · Triple M Rocks Footy AFL

NPR News: 09-22-2026 9PM EDT 4 min · 23 Sep 2026 · NPR News Now

9PM ET 09/22/2026 Newscast 3 min · 23 Sep 2026 · Fox News Hourly Update

Stories from our Elders: My passionate friendship with a rebel poet 51 min · 23 Sep 2026 · Conversations

The forgotten nutrient every midlife woman needs – with Dr Craig Rose 41 min · 23 Sep 2026 · Age Better with Liz Earle

Bringing Kashmir’s lakes back to life 25 min · 23 Sep 2026 · The Documentary Podcast

Report any issue

Source

Recorded05 Dec 2022

Publisherc.answersincme.com ↗

Handlerec:1447315

Show notes

Please visit answersincme.com/FDH860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in dermatology discusses the clinical evidence for novel Janus kinase (JAK) inhibitors for the treatment of moderate-to-severe atopic dermatitis. Upon completion of this activity, participants should be better able to: Describe the latest clinical evidence for novel JAK inhibitors in the treatment of moderate-to-severe AD; Outline practical strategies to manage adverse events associated with JAK inhibitors for the treatment of moderate-to-severe AD; and Identify patients with moderate-to-severe AD who might benefit from treatment with novel JAK inhibitors.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in